ArticleJournal of the Endocrine Society2026
Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma.
Article in Journal of the Endocrine Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with limited treatment options beyond first-line therapy, underscoring the need for effective salvage regimens. Objective: To evaluate the clinical activity and safety of gemcitabine and oxaliplatin (GemOx) in advanced ACC. Design: Retrospective cohort study conducted from April 2023 to April 2024 with longitudinal follow-up. Setting: Single-center tertiary referral cancer center. Patients or Other Participants: Fourteen patients with histologically confirmed advanced ACC treated with GemOx were included. Patients were heavily pretreated, with a median of 3 prior systemic therapies (range, 2-9); 43% had hormonally functional tumors. Interventions: Gemcitabine (1000 mg/m Main Outcome Measures: Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate per Response Evaluation Criteria In Solid Tumors 1.1 and treatment-related toxic effects. Results: After a median follow-up of 10.7 months (95% CI, 8.5-15.7), median PFS was 3.2 months (95% CI, 0.4-6.0) and OS was 13.0 months (95% CI, 3.6-22.5). Among 13 evaluable patients, 2 (15.4%) achieved partial response, 8 (61.5%) had stable disease, and 3 (23.1%) had progressive disease, yielding a disease control rate of 76.9%. No treatment-related deaths occurred. Conclusion: GemOx demonstrated modest clinical activity with manageable safety in heavily pretreated patients with advanced ACC. These findings suggest a potential role for GemOx as a salvage option, though validation in larger prospective studies is needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.